Open Innovation Booster and Lead Optimization consortium

DNDi’s open and collaborative approach to R&D – driven by patient needs, not profits – serves as a practical illustration of how alternatives to the prevailing system of commercial R&D can be organized and implemented, and how they can deliver for people in need. To speed up early-stage research and reduce overall R&D costs, DNDi works to enable research actors to actively collaborate without the restraints of intellectual property, supporting and coordinating a number of open innovation collaborations, including the NTD Drug Development Booster, Mycetoma Open Source project (MycetOS), and Open Synthesis Network (OSN).